RxDoctor Payments Data

Gnyandev Patel, MD

Internal Medicine · Lakewood, CANPI 1376593657

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Johnson & Johnson at 45.7% of the total. Reporting peaked in 2019 at $548 and has fallen 60.1% since, to $219 in 2024.

$1,914in general payments, 2019–2025

Across 52 payments — averaging $36.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$874
  • Acadia Pharmaceuticals Inc$667
  • Novo Nordisk$208
  • GSK$46
  • Amgen$23
  • Merck$23
  • plus $74 from 5 others
$3,113,781in research payments, 2019–2025

Across 29 payments — averaging $107,372 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$3.1M
  • Pfizer$19K
  • Eisai Inc.$6K
  • Janssen Research & Development, LLC$3K
  • Astrazeneca AB$750

What the payments were for

  • Food & beverage$1,914100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,914 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$21,682
Medicare patients
76
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate29$22,649
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,414
EliquisApixaban27$8,799
LinzessLinaclotide12$6,950
Levetiracetam113$6,109
XareltoRivaroxaban11$6,025
Divalproex Sodium67$4,507
Budesonide21$4,378
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,035
Pantoprazole Sodium72$3,653
Quetiapine Fumarate97$2,990
Carbamazepine34$2,107
Niacin ErNiacin13$1,714
Memantine Hcl31$1,703
Lacosamide21$1,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$23$22,64929 claims
GSKTrelegy Ellipta$46$10,41415 claims
PfizerEliquis$6$8,79927 claims
AbbVieLinzess$18$6,95012 claims
Johnson & JohnsonXarelto$874$6,02511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Lakewood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →